News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
